is tirzepatide still on the fda shortage list reconsidering its decision to take off its drug FDA: Shortage of Weight Loss

Consistency of timing (same day each week) matters far more than meal proximity

Moreover, improvements in mood observed in some patients during GLP1 therapy could relate to secondary benefits, such as weight loss, reduced glycemic variability, or enhanced selfefficacy, rather than a direct neurochemical effect

Advise patients using oral hormonal contraceptives to switch to a non-oral contraceptive method or add a barrier method of contraception for 4 weeks after initiation and for 4 weeks after each dose escalation with MOUNJARO [see Drug Interactions (7.2), Use in Specific Populations (8.3), and Clinical Pharmacology (12.3)]

The United States approved a tablet version of Wegovy late last year